Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It is indicated for relief of menopausal vasomotor symptoms, correction of estrogen deficiency, and prevention of osteoporosis in postmenopausal women.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable cold‑chain logistics where required. Our distribution network ensures timely delivery and regulatory documentation for import and resale globally.

Lenzetto is used in hormone replacement therapy to address estrogen‑related conditions.

Menopausal vasomotor symptoms: reduces the frequency and severity of hot flashes, night sweats and improves overall comfort during menopause. Estrogen deficiency: restores systemic estrogen levels, alleviating symptoms such as vaginal dryness, mood swings and fatigue in postmenopausal women. Prevention of osteoporosis: increases bone mineral density, thereby lowering the risk of fractures associated with postmenopausal bone loss.

Lenzetto may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Skin irritation at patch site: redness, itching or rash where the patch is applied. - Headache: mild to moderate tension‑type headaches. - Nausea: transient feeling of stomach upset. - Breast tenderness: mild swelling or discomfort in breast tissue.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack: cerebrovascular accidents. - Myocardial infarction: heart attack risk may increase. - Severe allergic reaction: anaphylaxis, angioedema or hives.

Before prescribing Lenzetto, clinicians should evaluate patient risk factors and follow safety guidelines. - Cardiovascular assessment: review history of thromboembolism, stroke or coronary artery disease. - Breast cancer screening: consider prior or current estrogen‑dependent malignancies. - Liver function monitoring: check hepatic impairment that may alter estradiol metabolism. - Bone health evaluation: assess baseline bone mineral density in osteoporosis prevention. - Concomitant estrogen use: avoid combining with other systemic estrogen products. - Store at room temperature: keep the patch in its original pouch, protect from moisture and direct sunlight.

Estradiol may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect leading to bleeding risk. - Oral contraceptives containing estrogen: additive estrogen exposure may raise thrombotic risk. - Tamoxifen: antagonistic effect reduces tamoxifen efficacy in breast cancer treatment.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may decrease estradiol plasma levels. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): can increase estradiol concentrations and side‑effect potential.